This post was originally published on this site

(MENAFN – GlobeNewsWire – Nasdaq) LONDON, April 01, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1×1’s at investor conferences through April 2021.

  • April 6 and 8, 2021 – Wells Fargo Annual Biotech Corporate Access
  • April 14, 2021 – 20th Annual Needham Virtual Healthcare Conference – As well as 1×1’s, the CEO and CFO will participate in a Fireside Chat at 10:15 AM ET. A webcast of the Fireside Chat will be available on the investor relations section of the Company’s website at Autolus .
  • April 22, 2021 – Raymond James Oncology Summit
  • April 28, 2021 – Kempen & Co. European Life Sciences: Gene, Cell, and RNA Day

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit .

Contact:

Julia Wilson
+44 (0) 7818 430877

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650

MENAFN01042021004107003653ID1101848595

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.